Skip to main content
Premium Trial:

Request an Annual Quote

Prostate Cancer Foundation Announces Grant Winners

NEW YORK (GenomeWeb News) – The Prostate Cancer Foundation is granting several million dollars through its Challenge Awards to three research programs that will use genomics-based projects in the effort to discover new treatments for recurrent prostate cancer.
Under the $19 million total funding the PCF said this week that it plans to grant to eight research groups, the organization will give between $500,000 and $1 million this week to scientists studying progression biomarkers, epigenetics, and molecular analysis for immunotherapy. These payments will be the first of three that PCF will spread over three years.
Massachusetts General Hospital’s research group will receive an award for biomarker-related studies that can help in analyzing the progression of prostate cancer.
The University of California, San Diego will use an award to study the epigenetic and genetic changes that result in prostate cancer.
PCF also is giving an award to Memorial Sloan Kettering Cancer Center to perform molecular analysis of patient response to immunotherapy for prostate cancer treatment.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.